With all the expectations for available Covid-19 vaccines based on the successful late-stage trial results reported by Pfizer/BioNTech and Moderna, the looming question is: when will the public be able to start getting the vaccines?

BioSpace takes a look at Moderna at the similarities between the two, and a few differencesPfizer-BioNTech and Moderna Covid-19 vaccines preliminary data readout of its COVID-19 vaccine suggested a 90% efficacy rate, the U.S. and western countries have the promise of two effective and reasonably safe vaccines. There are . Here’s a look.